Not Yet Recruiting PHASE2 INTERVENTIONAL 1-arm
NCT06883552
An Open-label, Single-arm Clinical Study of Stapokibart Injection in Combination with Tislelizumab Injection in Patients with Non-Small Cell Lung Cancer
Sponsor: Sichuan University
Conditions
Lung Cancer (NSCLC)
Interventions
Tislelizumab Injection
Updated 1 time since 2025 Last updated: Mar 13, 2025 Started: Oct 1, 2025 Primary completion: Oct 1, 2026 Completion: Oct 1, 2026
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.
A PHASE2 clinical study on Lung Cancer (NSCLC), this trial is actively recruiting participants. The trial is conducted by Sichuan University and has accumulated 1 data snapshot since 2025. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.
Status Flow
Change History
1 version recorded Not Yet Recruiting — PHASE2
[monthly]
Eligibility Summary
No eligibility information available.
Contact Information
Sponsor contact:
- Sichuan University
Data source: Sichuan University
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
No location information available.